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Treatment of newly diagnosed myeloma 
A. Palumbo and S.V. Rajkumar 
Abstract 
The introduction of thalidomide, bortezomib and lenalidomide has dramatically changed the treatment 
paradigm of multiple myeloma (MM). In patients eligible for autologous stem cell transplant (ASCT), 
combinations including thalidomide/dexamethasone (Thal/Dex) or bortezomib/dexamethasone (Bort/Dex) 
or lenalidomide/dexamethasone (Rev/Dex) have been introduced as induction regimens in patients eligible 
for ASCT. New induction regimens have significantly increased complete response rate before and after 
ASCT with a positive impact on progression-free survival. Maintenance therapy with thalidomide, under 
investigation with lenalidomide, may further prolong remission duration. In patients not eligible for ASCT, 
randomized studies have shown that melphalan, prednisone, thalidomide (MPT) and melphalan, 
prednisone and bortezomib (MPV) are both superior to melphalan and prednisone (MP), and are now 
considered standard of care. Ongoing trials will soon assess if MP plus lenalidomide may be considered an 
attractive option. More complex regimens combining thalidomide or bortezomib or lenalidomide with 
cyclophosphamide or doxorubicin have been also tested. In small cohorts of patients bortezomib or 
lenalidomide may overcome the poor prognosis induced by deletion 13 or translocation t(4;14) or deletion 
17p13. If these data will be confirmed, a cytogenetically risk-adapted strategy might become the most 
appropriate strategy. 
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Introduction 
Multiple myeloma (MM) accounts for approximately 10% of hematological malignancies, the frequency is 
constantly increasing due to aging of the general population.1, 2 At present, about 35% of myeloma patients 
are younger than 65 years, 28% are 65–74 years and 37% are older than 75 years.3 The current changes of 
the demographic curves will probably increase the incidence of elderly patients in the near future. In some 
patients, symptomatic myeloma evolves from an asymptomatic benign stage termed MGUS. In others, an 
intermediate asymptomatic premalignant stage referred to as smoldering MM can be recognized. The 
overall risk of progression from smoldering to symptomatic myeloma is 10% per year for the first 5 years, 
approximately 3% per year for the next 5 years and 1% for the next 10 years. The significant risk factors for 
progression included the amount of monoclonal protein and the extend of bone marrow involvement.4 No 
differences in overall survival were noted in patients with de novo myeloma or in those with a preceding 
diagnosis of plasma cell disorder such as MGUS or smoldering myeloma.5 To avoid the risk of an undue 
therapy in asymptomatic myeloma, the start of treatment requires the presence of at least one organ 
damage defined by hypercalcemia, anemia, renal insufficiency or bone lesions (CRAB criteria), which clearly 
define the occurrence of symptomatic myeloma. 
Recently, agents with novel mechanisms of action, such as thalidomide, bortezomib and lenalidomide, have 
shown significant activity in MM. Thalidomide and lenalidomide have antiangiogenesis properties, 
stimulate T- and natural killer cells and interfere with cytokines. They suppress growth factors such as 
interleukin-6, tumor necrosis factor-, inhibit myeloma cell adhesion and blood vessel growth cytokines such 
as vascular endothelial growth factor.6, 7 Bortezomib, a first in class proteasome inhibitor, specifically 
interferes with the 26S proteasome, which is responsible for degrading protein that control transcription, 
the cell-proliferation cycle and metabolism.8 Combinations of these agents with steroids, alkylating agents 
or anthracyclines have significantly improved response rate and progression-free survival (PFS). In a large 
group of newly diagnosed myeloma patients, no difference in overall survival was reported during a 24-year 
period from 1971 to 1994, there was a trend toward improvement during the period 1995–2000 and a 
statistically significant benefit in overall survival was shown during the last 6 years (2001–2006).9 These 
data suggest that autologous stem cell transplant (ASCT) was responsible for the trends seen during 1994–
2000, while novel agents contributed to the improvement observed since 2001. 
In newly diagnosed myeloma patients younger than 65 years, induction regimens including dexamethasone 
plus thalidomide or bortezomib or lenalidomide followed by high-dose melphalan and ASCT have 
significantly increased response rate. In elderly patients, usually older than 65 years, oral melphalan and 
prednisone (MP) has been combined with thalidomide or bortezomib significantly improving response rate 
and PFS. 
The future challenge is to define the optimal sequence and combination of these drugs to significantly 
impact the natural history of the disease. This paper will focus on the role of new drugs for frontline 
treatment of MM. 
Diagnosis 
A monoclonal protein can be detected by serum protein electrophoresis alone in 82% of patients and by 
serum immunofixation in 93%; a combination of serum and urine protein immunofixation studies improve 
the sensitivity to 97%.10 Less than 3% of patients have no evidence of monoclonal paraproteins (non-
secretory myeloma). The serum immunoglobulin-free light-chain assay negates the need of immunofixation 
and 24-h urine electrophoresis for purposes of diagnosis; the assay also allows the quantitative monitoring 
of patients with oligo-secretory or non-secretory myeloma. In addition, the baseline-free light-chain 
measurement represents a prognostic factor for myeloma.11 The diagnosis of MM requires 10% or more 
monoclonal plasma cells in the bone marrow and/or a presence of biopsy proven plasmacytoma, 
monoclonal protein in the serum and/or urine (except in patient with true non-secretory myeloma) and 
presence of end-organ damage felt related to the underlying plasma cell proliferative disorder: 
hypercalcemia (serum calcium >10 mg/l), renal insufficiency (serum creatinine >2 mg per 100 ml), anemia 
(hemoglobin <10 g per 100 ml), bone lytic lesions detected by skeletal survey.12 
   
Prognostic factors 
The clinical course of MM is quite heterogeneous: some patients die from disease evolution within few 
weeks, whereas others live for more than 10 years. Although very useful, it must be noted that most of the 
following parameters were studied before the advent of new active agents, and hence we need additional 
studies in the present era of novel therapy. 
The International Staging System (ISS) provides a simple, powerful and reproducible three-stage 
classification: stage I is characterized by b2-microglobulin less than 3.5 mg/l plus serum albumin > 3.5 g per 
100 ml and showed a median survival of 62 months; stage II is represented by neither stage I nor III and 
exhibited a median survival of 44 months; and stage III is defined by b2-microglobulin 5.5 mg/l with a 
median survival of 29 months.13 Acquired chromosomal abnormalities have shown to significantly impact 
survival in myeloma patients. Poor prognosis has been associated with the presence of immunoglobulin 
heavy chain translocations t(4;14), t(14;16), t(14;20), deletion 17p13 or deletion 13. By contrast a favorable 
prognosis has been observed in the presence of t(11;14), t(6;14) or hyperdiploidy.14, 15, 16 In a large study, 
the prognostic value of deletion 13 was almost entirely dependent on the association with t(4;14) and 
deletion 17p13. On a multivariate analysis, patients lacking t(4;14) and deletion 17p13 with a low b2-
microglobulin value had an excellent prognosis with a 4-year overall survival at 83%; patients presenting a 
single alteration either t(4;14) or deletion 17p13 or high b2-microglobulin value had an intermediate 
prognosis; while patients showing the cumulative alterations t(4;14) plus deletion 17p13 plus high b2-
microglobulin had a very poor prognosis with a median survival of only 19 months.16 It must be noted that 
the adverse impact of these cytogenetic abnormalities is firmly established in the context of conventional 
therapies but not with novel treatments. Bortezomib was shown to overcome the poor prognosis induced 
by deletion 13 and t(4;14) and deletion 17p13, whereas there is currently only preliminary data on efficacy 
with lenalidomide.17, 18 It is now strongly recommended that all newly diagnosed myeloma patients be 
tested at minimum for t(4;14), t(14;16) and deletion 17p13 by fluorescence in situ hydridization together 
with measurements of serum b2-microglobulin and lactate dehydrogenase.
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Treatment 
There is little evidence that early treatment of patients with asymptomatic MM prolongs survival compared 
with therapy delivered at the time of symptoms or end-organ damage. Clinical trials are ongoing to 
determine if new agents can delay progression of smoldering myeloma. Treatment choices are mainly 
based on age and presence of comorbidities. Preliminary data show that new drugs may overcome the 
poor prognosis induced by chromosomal aberrations such as deletion 13, t(4;14) or deletion 17p13. 
   
Treatment of myeloma in patients eligible for transplantation 
Initial therapy for patients is dependent on eligibility for ASCT, mainly determined by age, performance 
status and coexisting comorbidities. Protracted melphalan-based therapy should be avoided in patients 
with newly diagnosed myeloma who are considered eligible for ASCT, as it can interfere with adequate 
stem cell mobilization. Typically, patients are treated with approximately 2–4 cycles of induction therapy 
before stem cell harvest. This includes patients who are transplant candidates but who wish to reserve 
ASCT as a delayed option for relapsed refractory disease. Such patients can resume induction therapy 
following stem cell collection until a plateau phase is reached, reserving ASCT for relapse. 
The present choices for initial therapy are thalidomide/dexamethasone (Thal/Dex), 
bortezomib/dexamethasone (Bort/Dex) and related bortezomib-based combination regimens, and 
lenalidomide/dexamethasone (Rev/Dex). These regimens act rapidly and are associated with high-response 
rates; Thal/Dex and Rev/Dex have the added advantage of being orally administered. Thal/Dex and Rev/Dex 
are associated with an increased risk of deep vein thrombosis (DVT), necessitating routine 
thromboprophylaxis. New combinations including thalidomide, bortezomib or lenalidomide with 
chemotherapy agents, such as doxorubicin or cyclophosphamide, are currently under investigation. 
Thalidomide-based regimens 
Thalidomide and dexamethasone combination has increasingly been used instead of VAD. In 2005, a case-
matched control analysis showed that response rates with Thal/Dex were superior to those achieved with 
VAD (76 vs 52%).20 Randomized trials confirmed these findings.21, 22, 23 The Eastern Cooperative Oncology 
Group (ECOG) compared Thal/Dex to high-dose dexamethasone alone in 470 newly diagnosed myeloma 
patients. The overall response rate was significantly higher with Thal/Dex compared with dexamethasone 
(63 vs 46%; P<0.001). Time to progression was significantly longer with Thal/Dex compared with 
dexamethasone (median, 22.6 vs 6.5 months, P<0.001). DVT was more frequent with Thal/Dex (18.8 vs 
5.6%). Overall, grades 3–4 non-hematologic toxicities were seen in 79.5% of patients with Thal/Dex and 
64.2% with dexamethasone alone (P<0.001).24 In another trial, 204 patients were randomly assigned to 
receive induction treatment with Thal/Dex or with a VAD-like regimen followed by high-dose therapy and 
ASCT. The very good partial response (VGPR) rate was 34.7% in the Thal/Dex group and 12.6% in the VAD 
group (P=0.002) before ASCT. At 6 months post-transplant, the benefit of Thal/Dex was not further 
observed with VGPR rates of 44.4% in the Thal/Dex arm and 41.7% in the VAD arm (P=0.87).23 When 
thalidomide was incorporated into the high-dose therapy followed by ASCT, a higher complete response 
(CR) rate (62 vs 43%) and improved 5-year event-free survival (56 vs 44%) was observed compared with 
high-dose therapy without thalidomide.25 Unfortunately, the 5-year overall survival was similar in both 
groups (P=0.9). In the thalidomide group, a higher rate of thromboembolism (30 vs 17%) and peripheral 
neuropathy (27 vs 17%) were reported.25 In the Medical Research Council (MRC) Myeloma IX trial, which 
has recruited 900 patients, cyclophosphamide-thalidomide-dexamethasone (CTD) was compared with 
cyclophosphamide-VAD as induction regimen before ASCT. In a preliminary analysis, the CR rate was 20.3% 
after CTD and 11.7% after cyclophosphamide-VAD; this difference was maintained at 100 days post-ASCT, 
the CR rate was 58.2% after CTD plus ASCT and 41% after cyclophosphamide-VAD plus ASCT.26 Thalidomide-
based regimens provided superior rates of response when used as induction therapy in comparison with 
standard treatment. Further studies are needed to assess if this advantage is maintained after ASCT. The 
efficacy of this combination must be balanced against the greater toxicity and the need for antithrombotic 
prophylaxis. Patients receiving thalidomide in combination with high-dose steroids or chemotherapy need 
routine thromboprophylaxis. The presence of a central venous catheter, comorbidities, immobilization as 
well as the administration of high-dose dexamethasone, multi-agent chemotherapy may significantly 
increase the risk of thromboembolic events. In these conditions, coumadin (target INR 2–3) or low-
molecular weight heparin (equivalent of enoxaparin 40 mg once daily) are suggested for the first 4–6 
months of therapy. In patients lacking these risk factors aspirin can be used.27 
Lenalidomide/dexamethasone 
The Rev/Dex combination has shown significant activity in a phase II trial conducted at the Mayo Clinic. 
Thirty-one of 34 newly diagnosed patients (91%) achieved a partial response (PR), including 2 (6%) 
achieving CR, and 11 (32%) meeting criteria for VGPR.28 With a longer follow-up, 56% of patients achieved 
VGPR or better. In the subset of 21 patients receiving Rev/Dex as primary therapy without ASCT, 67% 
achieved VGPR or better.29 The 2-year time to progression was 71% for the entire cohort, including 66% of 
patients who received Rev/Dex without ASCT and 83% of those who received Rev/Dex with ASCT. 
Approximately, half of the patients experienced grade 3 or higher non-hematologic toxicity.29 In a recent 
study, 198 patients were randomly assigned to receive Rev/Dex or dexamethasone alone. The CR rate was 
significantly higher in the Rev/Dex group (22.4%). The superior response rate translated in a prolonged 
remission duration: the 1-year PFS was 77% in the Rev/Dex group and 55% in the dexamethasone group 
(P=0.002). ECOG tested Rev/Dex as administered in the Mayo Phase II trial (and in the regulatory 
relapsed/refractory myeloma studies) vs Rev/low-dose Dex (40 mg dexamethasone once weekly).30 Results 
show that toxicity rates are significantly higher with Rev/high-dose Dex compared with Rev/low-dose Dex. 
Early (first 4 month) mortality rates were low in both groups, 5 and 0.5%, respectively. The early mortality 
rate in the Rev/low-dose Dex group is probably the lowest reported in any large phase III trial, in which 
enrollment was not restricted by age or eligibility for stem cell transplantation. The DVT rates observed in 
this study were also low, making Rev/low-dose Dex one of the safest pretransplant induction regimens for 
myeloma. Although combinations including low-dose Dex are more appropriate, higher doses of 
dexamethasone should be considered in the presence of a very aggressive disease, in very young patients, 
or in the relapse setting. In a phase II trial, Rev/Dex was combined with clarithromycin (Biaxin), with this 
BiRD regimen the CR rate was particularly high (38.9%) including a 30.6% of stringent CR (immunofixation 
negative plus normal free light-chain ratio, plus a negative marrow biopsy by immunohistochemistry).31 The 
2-year PFS was 75.2% both in patients who subsequently received ASCT and those who did not receive any 
ASCT, and instead received continued BiRD treatment. Cyclophosphamide plus growth factor was used to 
mobilize stem cells, resulting in a successful harvest in all patients. The number of CD34 cells collected 
ranged from 4 to 21.5 CD34 X 106/kg.31 These studies confirm the high efficacy of lenalidomide in the 
upfront treatment of younger myeloma patients with a better safety profile compared with the parent 
compound thalidomide. In particular, the combination of lenalidomide with low-dose dexamethasone 
appears to be the more suitable option in this setting. The incidence of DVT is low with single-agent 
lenalidomide or Rev/low-dose Dex, but rises markedly when the agent is combined with high-dose 
dexamethasone. Recommendations for thromboprophylaxis are similar to those discussed above with 
Thal/Dex; aspirin alone is probably sufficient for patients receiving Rev/low-dose Dex.27 
Bortezomib-based regimens 
Bortezomib is a novel proteasome inhibitor approved by the FDA for the treatment of myeloma in patients 
who have failed one prior therapy. In newly diagnosed myeloma patients, the combination Bort/Dex 
showed an overall response rate of 66%, including 21% CR/near CR (nCR) and 10% VGPR.32 The most 
common side effects were gastrointestinal symptoms, peripheral neuropathy and fatigue. Peripheral 
neuropathy was grades 2–3 in 14% of patients. No DVTs and no hematologic toxicity greater than grade 2 
were observed. Grade 3 infections were recorded in five patients including three who had herpes zoster 
infections.29 To decrease toxicity and to assess efficacy Bort/Dex has been administered in an alternating 
schedule (bortezomib at 1.3 mg/mq bi-weekly, cycles 1, 3, 5 only) as induction therapy followed by ASCT. 
This alternating schedule induced a PR rate of 65%, including a CR rate of 12.5% and a VGPR rate of 10%. 
Toxicity was low with no grades 3–4 peripheral neuropathy or grades 2–4 thrombocytopenia. Chromosome 
13 deletion, t(4;14) and t(14;16) did not have a negative impact on response.33 In a randomized trial, 
Bort/Dex has been compared with VAD as induction therapy before ASCT.32 Response to induction showed 
a significant higher CR plus nCR rate for Bort/Dex (21.3 vs 8.3%), the superiority of Bort/Dex was 
maintained after ASCT: the CR plus nCR rates were 38 vs 28%. At the interim analysis, the 1-year PFS was 
93% for Bort/Dex and 90% for VAD.34 The combination bortezomib–dexamethasone–thalidomide has been 
compared with Thal/Dex in a randomized trial as induction treatment before double ASCT. The CR plus nCR 
rate was 36% with bortezomib–dexamethasone–thalidomide and 9% with Thal/Dex, and 57% with 
bortezomib–dexamethasone–thalidomide plus ASCT and 28% with Thal/Dex plus ASCT. Response to 
bortezomib–dexamethasone–thalidomide was not adversely affected by chromosome 13 deletion or 
t(4;14).35 In a phase II study, 100 patients received bortezomib, pegylated–liposomal–doxorubicin and 
dexamethasone before reduced intensity ASCT (melphalan 100 mg/m2). After induction with pegylated–
liposomal–doxorubicin and dexamethasone, the CR plus nCR rate was 23% and increased to 60% with 
pegylated–liposomal–doxorubicin and dexamethasone plus reduced intensity ASCT.36 A novel combination 
including bortezomib, lenalidomide and dexamethasone has been investigated, it produced high quality 
responses and was well tolerated in newly diagnosed patients. In 42 patients, this combination induced a 
PR rate of 98% including 52% VGPRs.37 The risk of DVT is low with bortezomib (<5%), while peripheral 
neuropathy can be higher, but alternating regimens significantly reduced this risk. Bortezomib-based 
regimens may be of value in patients with renal failure, and in those with adverse cytogenetic features such 
as t(4;14) or deletion 17p13. 
   
New maintenance approaches 
The concept of maintenance therapy may open new avenues for new treatment approaches in myeloma. In 
a large study, patients younger than 65 years were randomly assigned to receive no maintenance, 
pamidronate, or pamidronate plus thalidomide.38 The 3-year post-randomization probability of event-free 
survival (P<0.009) and the 4-year overall survival (P<0.04) were significantly prolonged in patients who 
received thalidomide. The incidence of thromboembolic events was not significantly different in the three 
groups. In another study, thalidomide–prednisone was compared with prednisone alone as maintenance 
therapy after ASCT: the 1-year PFS was 91 vs 69%, and the 2-year overall survival was 90 vs 81%, 
respectively.39 In both studies grades 3–4 peripheral neuropathy was significantly more prominent in the 
thalidomide group than in the controls. More recently, newly diagnosed patients received Thal/Dex as 
induction, they were then randomly assigned to tandem ASCT or single ASCT followed by thalidomide 
maintenance.40 The 3-year PFS was 57% in the double ASCT group and 85% in the single ASCT group, 
followed by thalidomide maintenance (P=0.02). This study is of particular interest because it shows the 
advantage of a maintenance approach, even in patients previously treated with Thal/Dex as induction 
therapy. Bortezomib also showed promising results as a maintenance therapy, suggesting that bortezomib 
maintenance may favorably impact time to recurrence.41 Additional studies are needed to determine the 
role of routine maintenance in myeloma, especially the use of lenalidomide, which has a better safety 
profile than thalidomide for long-term maintenance. 
Patients who are candidates for ASCT should follow a treatment strategy that includes ASCT. However, 
ASCT can be delayed until relapse if facilities are available to harvest and cryopreserve stem cells early in 
the disease course. Bortezomib- or lenalidomide-based regimens should be introduced as induction 
therapy before ASCT, as they significantly increase the VGPR and CR rates before transplantation. 
Thalidomide should be considered as maintenance after ASCT, specifically in patients who did not reach at 
least VGPR after single or tandem transplantation. The incorporation of new drugs as induction and 
maintenance therapy along with ASCT appears to produce VGPR rates slightly superior to those achieved by 
conventional chemotherapy with new drugs. Randomized trials are needed to directly compare the present 
best chemotherapeutic approach with best ASCT strategies and guide clinical practice for patients with 
MM. 
   
Treatment of myeloma in patients not eligible for ASCT 
Patients who are not candidates for transplant have been treated for years with standard alkylating agent 
therapy. In elderly patients, biological age may be quite different from chronological age, for this reason it 
is difficult to clearly define who is a candidate for ASCT and who is not. The inclusion in an ASCT program 
should always be considered in the absence of any serious heart, lung, renal and liver dysfunction, while an 
age limit should be considered and balanced with the biological age. With these limitations it is generally 
accepted that patients older than 65 years should not receive melphalan 200 mg/m2 followed by ASCT. In 
the age group between 65 and 70 years, intermediate-dose melphalan appears a suitable option. In a 
randomized study, patients, aged 65–70 years, received melphalan 100 mg/m2 or MP, and the reduced 
intensity ASCT program was superior to MP.42 In another study, patients, aged 65–75 years, received 
melphalan 100 mg/m2 or MP, ASCT was superior to MP in terms of response rate, but not in terms of PFS 
and overall survival.43 In the first study, 22% of patients did not complete the assigned treatment; in the 
second trial, 37% of patients did not complete it. According to these data, the age of 70 years should be 
considered as the age limit for intermediate-dose melphalan. Once again, the balance between efficacy and 
toxicities is extremely important to improve outcome. The discovery of novel therapies, targeting myeloma 
cells and the bone marrow microenvironment, has changed the treatment paradigm of myeloma therapy, 
especially for the elderly population. 
Thalidomide-based regimens 
In younger patients Thal/Dex significantly improves PFS in comparison with high-dose dexamethasone 
alone.24 In elderly patients, Thal/Dex was compared with MP in a randomized study. An interim analysis 
showed a significantly higher response rate in the Thal/Dex group but failed to show any advantage in PFS, 
while overall survival was superior in the MP group (P=0.02).44 Patients on Thal/Dex experienced more 
grades 2–3 neuropathy (25%) and skin toxicity (12%) compared with those on MP (8 vs 3%, respectively). 
Thromboembolic complications were seen in 8% of patients receiving Thal/Dex and in 3% of patients 
receiving MP. The higher toxicity rate of Thal/Dex regimen can explain the lower efficacy of Thal/Dex in the 
elderly population. This study raises the question if an alkylating agent is an essential component of drug 
combinations to improve treatment efficacy. Recently, MP has been combined with thalidomide (MPT) in 
four different randomized studies. In the first trial, oral MPT was compared with MP in patients aged 60–85 
years.45 The PR rates were 76% in the MPT group and 47.6% in the MP group, nCR or CR rates were 27.9 
and 7.2%, respectively. The 2-year event-free survival rates were 54% for MPT and 27% for MP (P=0.0006), 
with similar 3-year survival rates (P=0.19). In the second study, MPT was compared with MP and with 
intermediate-dose melphalan (100 mg/m2) followed by ASCT in patients aged 65–75 years. A higher PR rate 
was seen in the MPT and in the melphalan 100 mg/m2 groups, compared with MP (81 vs 76 vs 35%, 
respectively).43 Similarly, the CR rates were significantly higher with MPT and intermediate-dose melphalan 
compared with MP. Median PFS was 27.5 months in the MPT patients and 17.8 months in the MP group 
(P<0.0001), and median overall survival were 51.6 and 32.2 months, respectively (P=0.001). In the third 
study, patients aged 75 years and older were randomly assigned to receive MPT or MP plus placebo. The PR 
rate was 62% in the MPT group and 31% in the MP group, median PFS was 24.1 months for MPT and 19.0 
months for MP (P=0.001), and median overall survival was 45.3 months for MPT and 27.7 months for MP 
(P=0.03).46 In the fourth study, 362 patients with a mean age of 75 years (range, 49–92) received MPT or 
MP plus placebo. Results of an interim analysis showed better response rates and time to progression in 
the MPT group than in the MP group (P<0.03), but did not show any improvement in overall survival.47 
Results from these four randomized studies consistently showed better response rates and remission 
duration in patients assigned to MPT than in those receiving MP, but an overall survival benefit was only 
reported in the two French studies. Comparisons between different studies are difficult to make because of 
differences in patient populations, duration of treatment and use of maintenance regimens. Despite these 
differences, data strongly support the MPT as the new standard of care for elderly myeloma patients. In all 
studies, the MPT patients showed a higher incidence of grades 3–4 extra-hematological toxicities compared 
with the MP regimen, especially neurological adverse events, infections, cardiac toxicity and 
thromboembolism. Antithrombotic prophylaxis is recommended when using MPT. Recommendations for 
thromboprophylaxis are similar to those previously discussed with Thal/Dex.27 The higher toxicity rate 
significantly reduced the efficacy of the MPT combination. Randomized studies that used more strict 
inclusion criteria showed better outcome. In the French studies, a higher incidence of grades 3–4 
hematological toxicity (neutropenia and thrombocytopenia) was also observed, due to a higher number of 
MP cycles administered (12 cycles) and a higher dose of thalidomide (median dose 200 mg). The duration 
of MP treatment should be reduced from 12 cycles to 6 cycles, as prolonged melphalan exposure induces 
thrombocytopenia that hampers the delivery of subsequent effective salvage regimens. 
In the Medical Research Council (MRC) Myeloma IX trial, CTD has been compared with MP in 900 patients. 
In the CTD group, the PR rate (82 vs 49%) and the CR rates (23 vs 6%) were significantly superior in the CTD 
group.26 Unfortunately, data on remission durations are not available; if they also are superior to MP, the 
CTD regimen should be added as an alternative standard frontline approach for elderly patients. 
Lenalidomide-based regimens 
The Italian group evaluated in a phase I/II trial, dosing, safety and efficacy of melphalan plus prednisone 
and lenalidomide in newly diagnosed elderly myeloma patients.48 The maximum tolerated dose was 
considered to be melphalan at 0.18 mg/kg on days 1–4, prednisone at a 2-mg/kg dose on days 1–4 and 
lenalidomide at 10 mg on days 1–21, every 28 days for nine cycles. Aspirin was given as a prophylaxis for 
thrombosis. Eighty-five percent of patients achieved at least a PR, and 23.8% achieved immunofixation-
negative CR. The 1-year event-free and overall survival was 92 and 100%, respectively. Grades 3–4 adverse 
events were mainly related to hematologic toxicities (neutropenia 66%). Severe non-hematologic side 
effects were less frequent and included febrile neutropenia (8%), cutaneous rash (10%) and 
thromboembolism (6%). Preliminary results showed that the event-free survival of patients with deletion of 
chromosome 13 or chromosomal translocation (4;14) was not significantly different from those who did not 
have such abnormalities. This study formed the basis for the ongoing international phase III study 
comparing MP vs melphalan plus prednisone and lenalidomide. In the near future, the MPT combinations 
will be challenged by the recent results reported with Len/Dex, using low-dose dexamethasone (40 mg on 
days 1, 8, 15 and 22, every 4 weeks). Neutropenia and DVT are the major complications with lenalidomide, 
although the addition of aspirin markedly reduced the risk of thromboembolic events in newly diagnosed 
patients treated with lenalidomide in association with dexamethasone or chemotherapy. 
Recommendations for thromboprophylaxis have already been discussed, with lenalidomide aspirin seems 
to be the preferred choice in the absence of additional risks of thromboembolism.27 The addition of 
granulocyte-colony stimulating factor is recommended in case of neutropenia, and melphalan dose 
reduction (from 0.18 to 0.13 mg/kg) should always be applied in the presence of severe neutropenia 
despite granulocyte-colony stimulating factor. 
Bortezomib based-regimens 
The Spanish cooperative group conducted a large phase I/II trial of bortezomib, melphalan and prednisone 
(MPV).49 The association showed encouraging results: PR rate was 89%, including 32% immunofixation-
negative CR, half of them achieved immunophenotypic remission (no detectable plasma cells at 10-4 to 10-5 
sensitivity). PFS at 16 months for VMP patients was significantly prolonged in comparison with historical 
controls treated with MP only (91 vs 66%), similarly overall survival at 16 months was improved (90 vs 
62%). Interestingly, response rate, PFS and overall survival were similar among patients with or without 
chromosome 13 deletion or IgH translocations. Grades 3–4 adverse events observed with MPV were mainly 
thrombocytopenia, neutropenia, peripheral neuropathy, infections and diarrhea. The treatment appeared 
more toxic in patients older then 75 years. Bortezomib can induce transient thrombocytopenia and 
peripheral neuropathy. Pre-existing neuropathy or previous neurotoxic therapy increases the risk of 
peripheral neuropathy, which can be reduced or resolved by prompt dose reduction of the drug. 
Bortezomib may enhance the incidence of infections, in particular, herpes zoster reactivation, and 
prophylactic antiviral medications are highly recommended. These data have recently been confirmed in a 
large randomized trial comparing MPV with MP and have provided the basis for MPV as an alternative 
standard of care for elderly patients.50 
The efficacy of these new regimens should be balanced against their higher toxicities: in the presence of 
high risk of thromboembolism, MPV could be the preferred option; in the presence of peripheral 
neuropathy, MPR should be considered; in patients with renal insufficiency, MPV is better tolerated; and 
MPT should be considered if costs are a concern. Oral treatment should also be balanced vs intravenous 
treatment, as the latter is more invasive. 
   
Management of bone disease 
Bone lytic disease is the most frequent complication of myeloma. Pamidronate and zoledronic acid are the 
cornerstone for the treatment of lytic disease in myeloma. Concerns have risen during the last years about 
their renal side effects and osteonecrosis of the jaw, a complication which is related to long-term use of 
potent biphosphonates.51 The discovery of novel agents with a beneficial effect on abnormal bone 
remodeling of myeloma is highly expected. Bortezomib has special effects on myeloma bone metabolism. 
Bortezomib increased the number of osteoblastic cells/mm2 and the Runx2/Cbfa1-positive osteoblasts in 
bone biopsies of responding myeloma patients, but not in those who did not respond.52 In addition to 
promoting bone formation, bortezomib has been reported to affect osteoclast differentiation and function. 
Bortezomib was shown to inhibit osteoclast differentiation in a dose- and time-dependent manner, as well 
as inhibit the bone resorption activity of osteoclasts.53 The results of these studies indicate that bortezomib 
may be the first agent that combines potent antimyeloma activity with potential beneficial effects on bone 
(Tables 1, 2 and 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 - Treatment schema. 
  
 
 
 
 
 
 
 
Table 2 - Efficacy of regimens used as frontline treatment in multiple myeloma. 
  
Table 3 - Safety of regimens used as frontline treatment in multiple myeloma. 
 
   
Conclusions 
High-dose melphalan followed by ASCT in younger patients and oral MPT or MPV in elderly patients are the 
standard of care for the frontline therapy of myeloma. Survival after transplant appears to be related to the 
achievement of CR or VGPR. Improved response rate after induction treatment, before transplant, could 
translate to better results after high-dose therapy with prolonged survival. In younger patients, 
combinations incorporating thalidomide or lenalidomide or bortezomib significantly increase the 
pretransplant CR plus VGPR rate before high-dose melphalan and autologous transplantation. These 
combinations may further improve the CR plus VGPR rate achieved after transplant. A reasonable 
alternative approach is to collect stem cell at diagnosis and leave the ASCT option for relapse. Both 
approaches need the evidence of efficacy from the ongoing prospective randomized studies. These 
evidences should always include at least data on PFS advantage. If survival improvement represents the 
ultimate goal, response advantage is not adequate, by itself, to define treatment efficacy. 
Cytogenetic abnormalities, such as chromosome 13 deletion or t(4;14), are considered negative prognostic 
factors. Unfortunately, most of the studies reported to date have not prospectively stratified patients 
based on cytogenetic abnormalities, making a firm conclusion difficult. In a small cohort of patients 
receiving bortezomib or lenalidomide, the PFS of patients with deletion of chromosome 13 or chromosomal 
translocation (4;14) was not significantly different from those who did not show such abnormalities. It must 
however, be mentioned that irrespective of cytogenetic 'risk profile,' MM remains incurable. To determine 
the optimal regimen for each individual patient based on a cytogenetically adapted strategy, 
comprehensive study and long-term follow-up is required. 
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